Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Mette S. van Ramshorst"'
Autor:
Tessa G Steenbruggen, Gabe S. Sonke, Erik van Werkhoven, Sabine C. Linn, Sabine Siesling, Marleen Kok, Vincent O. Dezentjé, Mette S. van Ramshorst
Publikováno v:
European journal of cancer, 135, 66-74. Elsevier
European Journal of Cancer, 135, 66-74. Elsevier Limited
European Journal of Cancer, 135, 66-74. Elsevier Limited
Background Recommendations on adjuvant chemotherapy in pT1N0M0 triple-negative breast cancer (TNBC) differ among international guidelines owing to lack of randomized trial data. We evaluated associations of adjuvant chemotherapy with a long-term outc
Autor:
Marie-Jeanne T. F. D. Vrancken Peeters, Emma J. Groen, Mette S. van Ramshorst, Frederieke van Duijnhoven, Ritse M. Mann, Esther H. Lips, Jelle Wesseling, Gabe S. Sonke, Michael Schaapveld, Marieke E. M. van der Noordaa
Publikováno v:
Breast Cancer Research and Treatment, 189, 213-224
Breast Cancer Research and Treatment, 189, 1, pp. 213-224
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 189, 1, pp. 213-224
Breast Cancer Research and Treatment
Purpose The presence of extensive ductal carcinoma in situ (DCIS) adjacent to HER2-positive invasive breast cancer (IBC) is often a contra-indication for breast-conserving surgery, even in case of excellent treatment response of the invasive componen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adf29fcec7f5f5dd928682cd323e1e44
http://hdl.handle.net/2066/238668
http://hdl.handle.net/2066/238668
Autor:
Aafke H. Honkoop, Marie-Jeanne T. F. D. Vrancken Peeters, I.A.M. Mandjes, Caroline M.P.W. Mandigers, Irma M. Oving, Annelie J. Vulink, Lidwine W. Tick, Anna van der Voort, Inge Kemper, GS Sonke, Sabine C. Linn, Agnes J. van de Wouw, Mette S. van Ramshorst, Laurence J. C. van Warmerdam, Erik van Werkhoven, Jelle Wesseling
Publikováno v:
JAMA Oncology. 7:978
Importance Primary analysis of the TRAIN-2 study showed high pathologic complete response rates after neoadjuvant chemotherapy with or without anthracyclines plus dualERBB2(formerlyHER2) blockade. Objective To evaluate 3-year event-free survival (EFS
Autor:
Sabine C. Linn, Gabe S. Sonke, I.A.M. Mandjes, Inge Kemper, Carolien H. Smorenburg, Aafke H. Honkoop, Erik van Werkhoven, Jacqueline M. Stouthard, Irma M. Oving, Mette S. van Ramshorst, Vincent O. Dezentjé
Publikováno v:
The Breast. 29:153-159
Background The addition of pertuzumab to neoadjuvant trastuzumab-based chemotherapy improves pathologic complete response rates in HER2-positive breast cancer. However, increased toxicity has been reported with the addition of pertuzumab, and this ma
Autor:
Gabe S. Sonke, Maartje van Seijen, Mette S. van Ramshorst, Esther H. Lips, Jelle Wesseling, Tessa G Steenbruggen, Liselore Maria Janssen, Erik van Werkhoven, Marie-Jeanne T. F. D. Vrancken Peeters
Publikováno v:
Clinical cancer research, 25(16), 4985-4992. American Association for Cancer Research Inc.
Purpose: In breast cancer, pathologic complete response (pCR) to neoadjuvant systemic therapy (NST) is associated with favorable long-term outcome. Trastuzumab emtansine as additional adjuvant therapy improves recurrence-free survival of patients wit
Autor:
Gwen M. H. E. Dackus, Margriet van der Heiden-van der Loo, Mette S. van Ramshorst, Sabine C. Linn, Gabe S. Sonke
Publikováno v:
Breast Cancer Research and Treatment, 158(2), 361. Springer New York
The prognosis of patients with stage II–III Human Epidermal growth factor Receptor 2 (HER2)-positive breast cancer has significantly improved since the addition of trastuzumab to (neo-)adjuvant chemotherapy. Several reports have shown that small (
Autor:
Inge Kemper, I.A.M. Mandjes, Agnes J. van de Wouw, Marie-Jeanne T. F. D. Vrancken Peeters, Aafke H. Honkoop, Anna van der Voort, Laurence J. C. van Warmerdam, Caroline M.P.W. Mandigers, Irma M. Oving, Annelie J. Vulink, Sabine C. Linn, Lidwine W. Tick, Mette S. van Ramshorst, Erik van Werkhoven, Jelle Wesseling, Gabe S. Sonke
Publikováno v:
Journal of Clinical Oncology. 38:501-501
501 Background: The multicenter phase III TRAIN-2 study showed high pathological complete response (pCR) rates after neoadjuvant chemotherapy with and without anthracylines plus dual HER2-blockade in stage II-III HER2-positive breast cancer patients
Autor:
Marleen Kok, Tessa G Steenbruggen, Mette S. van Ramshorst, Carolien H. Smorenburg, Sabine C. Linn, Gabe S. Sonke
Publikováno v:
Drugs, 77(12), 1313. Adis International Ltd
In the last decade, the systemic treatment approach for patients with early breast cancer has partly shifted from adjuvant treatment to neoadjuvant treatment. Systemic treatment administration started as a ‘one size fits all’ approach but is curr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d75bdf1ade3533d2add5fd6c159857e8
https://dspace.library.uu.nl/handle/1874/355879
https://dspace.library.uu.nl/handle/1874/355879
Autor:
Marie-Jeanne T. F. D. Vrancken Peeters, Jelle Wesseling, Mette S. van Ramshorst, Gabe S. Sonke, Emilie J. Groen, Claudette E. Loo, Gonneke Winter-Warnars, Frederieke van Duijnhoven
Publikováno v:
Breast cancer research and treatment. 164(1)
Neoadjuvant treatment of HER2-positive breast cancer frequently leads to a pathologic complete response (pCR), which is associated with favourable long-term outcome. Treatment regimens typically consist of 6-9 cycles of trastuzumab-based chemotherapy
Autor:
Suzana C Teixeira, Bas B. Koolen, Jelle Wesseling, Marie-Jeanne T. F. D. Vrancken Peeters, Emiel J. Th. Rutgers, Gabe S. Sonke, Sjoerd Rodenhuis, Renato A. Valdés Olmos, Mette S. van Ramshorst, Kenneth E. Pengel, Kenneth G. A. Gilhuijs, Wouter V. Vogel
Publikováno v:
Cancer Imaging, Vol 17, Iss 1, Pp 1-8 (2017)
Cancer imaging, 17(1). e-med
Cancer Imaging, 17(1). e-med
Cancer Imaging
Cancer imaging, 17(1). e-med
Cancer Imaging, 17(1). e-med
Cancer Imaging
Background 18F-FDG PET/CT can monitor metabolic activity in early breast cancer during neoadjuvant systemic therapy (NST), but it is unknown if the metabolic breast and axillary response differ. We evaluated the correlation between metabolic breast a